Mason Freeman, M.D., is a Professor of Medicine at Harvard Medical School and a Venture Partner at 5AM Ventures. He also serves as Chief of the Lipid Metabolism Unit and Director of Massachusetts General Hospital’s (MGH) Translational Research Center. Trained in internal medicine and endocrinology, Dr. Freeman has spent 25 years studying the trafficking of lipids in and out of cells via receptors and transmembrane transporters. Previously, he led the Novartis Translational Medicine Program for Cardiovascular & Metabolic Diseases and was Global Head of Biomarker Development. At Novartis and 5AM, Dr. Freeman contributed to the development of ENTRESTO for heart failure and VELTASSA for hyperkalemia. Dr. Freeman currently is a Director of Crinetics Pharmaceuticals and previously served as Clinical Advisor to Relypsa and a Director for Envoy (acquired by Takeda). He holds a B.A. from Harvard College, an M.D. from the University of California, San Francisco and completed a postdoctoral research fellowship in the Biology department at MIT and the Endocrine Department at MGH.